Stroke treatment window could expand to 72 hours in new trial

NCT ID NCT06954155

Recruiting now Disease control Sponsor: Beijing Tiantan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the clot-busting drug tenecteplase can help people who have had a stroke 24 to 72 hours earlier. Currently, such drugs are only given within a few hours. The trial will compare tenecteplase to standard care (blood thinners) in 330 adults with blocked brain arteries. The goal is to see if more patients can live independently at 90 days.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tenecteplase (a clot-busting drug given as a single injection)
What this could lead to: If it works, this could extend the time window for treating strokes from hours to days, helping more people recover with less disability.
What could go wrong: This is an early phase 3 trial with only 330 participants. The drug may not improve outcomes and carries a risk of bleeding in the brain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

STROKE

Contacts and locations

Locations

Beijing tiantan hospital
RECRUITING

Beijing, 100070, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.